Trials / Unknown
UnknownNCT04306926
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
A Open-label, Single-arm, Phase II Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 1200mg administered IV on Day 1 of each 21-day cycle. |
| RADIATION | SBRT | Give according to the location of the lesion and clinical condition. |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2022-10-31
- Completion
- 2023-05-30
- First posted
- 2020-03-13
- Last updated
- 2020-03-13
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04306926. Inclusion in this directory is not an endorsement.